Randall E. Harris – författare

Epidemiology of Chronic Disease: Global Perspectives is the most current and authoritative resource on the epidemiology, etiology, pathogenesis, risk factors and preventive factors of over 5 major chronic diseases and conditions. This comprehensive text provides readers with an excellent basis for examining current hypotheses regarding chronic disease epidemiology.Organized into five sections, the text begins with an introductory chapter which examines the new public health environment in which chronic diseases have replaced acute infectious conditions concurrent with improved health care and increasing longevity in many populations of the world.Subsequent sections cover cardiovascular and cerebrovascular diseases, major forms of cancer, diseases of the respiratory tract, metabolic and digestive diseases, musculoskeletal diseases, neurodegenerative diseases, and finally, three infectious diseases that often manifest as chronic conditions. Special sections in each chapter focus on controversial topics that can serve as a launching point for classroom discussion of molecular mechanisms of disease pathogenesis and the relevant epidemiologic issues pertaining to the prevention and control of chronic diseases.Key Features:- Special sections in each chapter focus on controversial topics that can serve as a launching point for classroom discussion of molecular mechanisms of disease pathogenesis and the relevant epidemiologic issues pertaining to the prevention and control of chronic diseases.- Four new chapters on the epidemiology of congestive heart failure, peripheral artery disease and aortic dissection, venous thromboembolism and pulmonary embolism, and sudden cardiac death. - Discussion of new findings, such as the association of post-traumatic stress disorder (PTSD) with suicide and the emerging crisis of antibiotic resistance in tuberculosis and other chronic infections.- Updated epidemiologic findings and references throughout.- Robust instructor's materials, including an online instructor's manual with recommended questions and answers for each chapter, slides in PowerPoint format, and a test bank.

In this book, a worldwide panel of leading experts discuss the role of inflammation in the pathogenesis of major chronic diseases and the current controversy regarding risk versus benefit of selective cyclooxygenase-2 (COX-2) inhibitors. The authors provide exciting and enlightening perspectives on COX-2 and related molecular targets in the future of medicine, including historical perspectives.

This book chronicles the evidence for the chemopreventive and therapeutic effects of cyclooxygenase-2 (COX-2) inhibitors against virtually all forms of cancer and presents exciting new opportunities for the use of COX-2 blockade in its prevention and treatment. The authors elucidate the process by which COX-2 inhibitors interrupt prostaglandin biosynthesis and cancer development, examine the positive epidemiological effects of such NSAIDs as aspirin and ibuprofen on various cancers, and demonstrate through animal models that COX-2 inhibitors and NSAIDs inhibit a variety of malignant neoplasms in vivo. They also present genetic models confirming the critical role of COX-2 in carcinogenesis and discuss how its molecular biology modulates carcinogenesis. In addition, the authors review the clinical applications of selected NSAIDs that are immediately relevant to cancer prevention and control and outline the future prospects of COX-2 blocking agents.

This book chronicles the evidence for the chemopreventive and therapeutic effects of cyclooxygenase-2 (COX-2) inhibitors against virtually all forms of cancer and presents exciting new opportunities for the use of COX-2 blockade in its prevention and treatment. The authors elucidate the process by which COX-2 inhibitors interrupt prostaglandin biosynthesis and cancer development, examine the positive epidemiological effects of such NSAIDs as aspirin and ibuprofen on various cancers, and demonstrate through animal models that COX-2 inhibitors and NSAIDs inhibit a variety of malignant neoplasms in vivo. They also present genetic models confirming the critical role of COX-2 in carcinogenesis and discuss how its molecular biology modulates carcinogenesis. In addition, the authors review the clinical applications of selected NSAIDs that are immediately relevant to cancer prevention and control and outline the future prospects of COX-2 blocking agents.